Resistance to apoptosis, often achieved by the overexpression of antiapoptotic proteins, is common and perhaps required in the genesis of cancer. However, it remains uncertain whether apoptotic defects are essential for tumor maintenance. To test this, we generated mice expressing a conditional BCL-2 gene and constitutive c-myc that develop lymphoblastic leukemia. Eliminating BCL-2 yielded rapid loss of leukemic cells and significantly prolonged survival, formally validating BCL-2 as a rational target for cancer therapy. Loss of this single molecule resulted in cell death, despite or perhaps attributable to the presence of other oncogenic events. This suggests a generalizable model in which aberrations inherent to cancer generate tonic death signals that would otherwise kill the cell if not opposed by a requisite apoptotic defect(s).
Figure 1. Construction of a conditional BCL-2 transgenic mouse
A: A conditional BCL-2 allele. A human BCL-2 cDNA under the control of a minimal CMV promoter adjacent to a heptamer of the tet operon (tet-BCL-2) locus was targeted into the DNA methyltransferase I (DMT1) locus. Shown is a schematic of the wt DMT1 locus, the 4 kb EcoRV to Bgl II targeting construct, and final tet BCL-2 knockin DMT1 locus following cre-mediated deletion of the selectable marker. At bottom are representative Southern blots of correctly integrated (ϩ) and nontargeted (Ϫ) clones. B: Doxycycline eliminates BCL-2 expression. Extracts from dissociated splenocytes from doubly transgenic mice were subjected to immunoblot for BCL-2. Left two lanes are from mice that received no doxycycline; right two lanes are from mice that received 200 g/ml in drinking water for 2 weeks prior to sacrifice.
for maintaining as well as developing a cancer, we generated not develop malignancies and demonstrated normal survival (not shown). a mouse model in which the expression of BCL-2 is conditional.
Results

tet-BCL-2/MMTV-tTA/E-myc mice develop a lymphoblastic leukemia
Since BCL-2 oncogenesis requires additional aberrations, we A conditional BCL-2 trangene is tightly controlled by doxycycline introduced deregulated c-myc, since this is a naturally occurring secondary event known to complement BCL-2 in mouse and We obtained germline transmission of a knockin allele in which a human BCL-2 cDNA under the control of multimerized tethuman lymphomagenesis (Gauwerky et al., 1988; McDonnell and Korsmeyer, 1991; Schmitt et al., 2000; Strasser et al., 1993; operons (Gossen et al., 1995) adjacent to a minimal CMV promoter was targeted to the DNA methyltransferase1 (DMT1) locus Vaux et al., 1988) . Mice singly transgenic for E-myc develop a bulky B cell lymphoma, with a relatively normal white blood (tet-BCL-2) ( Figure 1A ). The DNA methyltransferase 1 (DMT1) locus was chosen for its high rate of integration and consistent count (WBC) until late in the course of malignancy (Adams et al., 1985) . In a nonconditional model, mice expressing both expression patterns (Li et al., 1992) . tet-BCL-2 mice were intercrossed with a line bearing the tetracycline transactivator (tTA) BCL-2 and c-myc under the control of the immunoglobulin enhancer (E) develop an immature lymphoblastic leukemia within under control of the MMTV promoter (MMTV-tTA), known to express tTA in spleen as well as epithelial tissues (Hennighausen days of birth . Similarly, our triply transgenic (tet-BCL-2/MMTV-tTA/E-myc) mice uniformly developed lymphet al., 1995; Huettner et al., 2000) . Progeny bearing both alleles (doubly transgenic) expressed BCL-2 in splenocytes and bone oblastic leukemia by 2 weeks of age (WBC ‫/000,05ف‬l). Over weeks, the WBC rose to 2 ϫ 10 5 to 2 ϫ 10 6 per microliter. marrow cells as well as in epithelial cells, including mammary, sebaceous, salivary, basal epidermal cells, thymic epithelium,
The bone marrow was replaced with lymphoblasts expressing human BCL-2 ( Figures 2C-2F ), which also infiltrated the spleen and testes (data not shown). BCL-2 expression was effectively ablated when doxycycline was added to the drinking water (Figures 2A and 2B) , resulting in marked splenomegaly (spleen weight 5-to 10-fold Ͼ wt mice). Lymphoblasts effaced the ( Figure 1B ). At 18 months of age, doubly transgenic mice did Figure 3A ). Four of 14 characterized leukemias were less mature pre-pro-B cells (CD43 ϩ , B220 Figure 3A ; Allman et al., 1999; Hardy and Hayakawa, 2001) . To further assess the stage of differentiation as well as clonality of the leukemias, we assessed the configuration of immunoglobulin (Ig) heavy chain gene loci. Pre-pro-B cell leukemias displayed a germline pattern, as expected, whereas the pro-B to pre-B cell stage leukemias demonstrated gene rearrangements indicative of monoclonal or oligoclonal expansions of cells ( Figure 3B ). As a further assessment of clonality and genomic instability, spectral karyotypes (SKY) were performed. A representative karyotype of a pro-/pre-B cell stage leukemia revealed clonal abnormalities and evidence for genomic instability, including extra chromosomes 6 and 12 ( Figure 3C ).
BCL-2 is required for leukemia maintenance
To assess whether BCL-2 is required to maintain lymphoblastic leukemia, we followed a matched cohort of 5-to 7-week-old triply transgenic mice with leukemia, 14 of which received doxycycline and 14 of which remained untreated. Administration of doxycycline reduced the level of BCL-2 in peripheral mononuclear cells within 3 days ( Figure 4A ) and resulted in a dramatic reduction in the WBC ( Figures 4B-4D ). Mice treated with doxycycline, with only one exception, normalized their WBC over 10 days of treatment ( Figure 4B ). A subsequent cohort of mice revealed that the bone marrow was no longer replaced by leukemic lymphoblasts and demonstrated the resumption of normal trilineage hematopoiesis ( Figures 4E and 4F ). Moreover, within 2 weeks of treatment, the spleen returned to normal ( Figure 4G ).
Apoptosis of lymphoblasts was noted in the bone marrow of mice 48 hr following initiation of doxycycline (Figures 5A and 5B) . Addition of doxycycline to cultured primary leukemia cells from the bone marrow of triply transgenic mice resulted in apoptotic death, providing evidence for a cell-autonomous effect of eliminating BCL-2 ( Figure 5C ). Leukemic mice that demonstrated overt signs of illness (lethargy, hunched posture, tachypnea, and loss of skin turgor) resumed normal activity when the The late deaths of doxycycline-treated triply transgenic mice G: Leukemia cells from tet-BCL-2/MMTV-tTA/E-myc mouse efface lymph node architecture and invade adjacent fat, HϩE.
resulted from a bulky B cell lymphoma, essentially indistinguish-H: Leukemic cells from tet-BCL-2/MMTV-tTA/E-myc mouse invade liver, able in phenotype, histology, WBC, and tissue distribution to that developing in singly transgenic E-myc mice (Adams et al., 1985) . Moreover, the time of onset of these tumors and the median survival of doxycycline-treated triply transgenic mice (145 days) is also comparable to that of the 15 singly transgenic lymph node architecture ( Figure 2G ) and often infiltrated other E-myc mice (146 days) followed in our study, and their survival tissues including the liver ( Figure 2H ). curves do not differ significantly (p ϭ 0.55; Figure 6A ). These Immunophenotypic analysis revealed that all leukemic cells late-onset B cell lymphomas would be expected since the conwere of B lymphocyte origin. The majority of leukemias represtitutive c-myc transgene expression continues unabated, as it sented a continuum from pro-B cell (CD43 ϩ , B220
is not responsive to doxycycline. Only an occasional late-onset Ϫ leukemias demonstrate a recombined pattern. One displays a monoclonal (M) and four an oligoclonal (O) pattern. As a control for DNA quality and loading, the blot was stripped and reprobed for MCL-1, shown at bottom. C: Spectral karyotype of a leukemia demonstrating a clonal abnormality. Shown is the dominant karyotype: 42, XY, ϩ6, ϩ12. lymphoma in doxycycline-treated mice possessed human Treatment with doxycycline once again eliminated the leukemic cells from the blood ( Figure 6C ) and substantially extended BCL-2 expression, ruling out an escape from doxycycline regulation as the explanation for progression in the majority of tumors survival in all the recipient groups ( Figure 6D ). (Figure 6B ). A unique Ig gene rearrangement, distinct from the original tumor, was noted in a late-onset lymphoma of a doxycyDifferential sensitivity of mitochondria from cline-treated mouse supporting the emergence of a clonally lymphoblastic leukemias versus nonmalignant distinct tumor ( Figure 6E ). In summary, the late-onset B cell FL5.12 cells to BAX oligomerization lymphomas that follow ablation of BCL-2 expression resemble and cytochrome c release E-myc driven lymphomagenesis. This is consistent with the The rapid induction of apoptosis that proved coordinate with emergence of independent lymphomas, although a clonal relathe elimination of BCL-2 in the triply transgenic lymphoblasts tionship with the initial leukemia can not be completely excluded prompted us to assess whether overexpressed BCL-2 was sewith available technologies. Such E-myc-expressing tumors questering BH3-only proteins that were chronically activated by could be expected to acquire a complementary aberration in myc-driven oncogenesis. To test this, we purified mitochondria apoptosis; however, these spontaneous, secondary events from FL5.12 (a nonmalignant pro-B lymphocyte line) and from would not be under the control of doxycycline.
triply transgenic pro-B lymphoblastic leukemia cells to compare their differential susceptibility to apoptosis. An "activating" BH3 domain (BIM) induced the activation and oligomerization of BAX The transplantable leukemia is susceptible to doxycycline ablation of BCL-2 and BAK and resulted in release of cytochrome c from normal FL5.12 mitochondria and leukemia mitochondria (Figures 7A The transplantability of a tumor is a standard measure of its malignant potential. Three cohorts of sublethally irradiated (650 and 7B; Letai et al., 2002; Wei et al., 2001) . In contrast, a "sensitizing" BH3 domain (BAD) cannot activate BAX or BAK directly, rad) recipient mice received from 1.0 ϫ 10 6 to 2.5 ϫ 10 6 bone marrow cells from triply transgenic donor mice with pre-pro-B but does bind antiapoptotic BCL-2 with high affinity and will displace other activator BH3 peptides present in the BCL-2 or pre-B cell leukemia. In each cohort, bone marrow cells from leukemic mice, when injected into irradiated recipient mice, pocket (Letai et al., 2002; Wei et al., 2001 ). Whereas FL5.12 mitochondria are unaffected, the mitochondria from the lymphtransferred a lethal lymphoblastic leukemia (Figures 6C and 6D) . Abnormalities in genes affecting apoptosis have been found and 7B). Consistent with this, the sensitizing BAD BH3 domain in nearly every cancer, suggesting they may be necessary to induces the oligomerization of BAX in mitochondria from lymphdevelop cancer (Green and Evan, 2002; Hanahan and Weinberg, oblastic leukemia cells, but not the mitochondria from normal 2000; Schmitt, 2003) . Consequently, the apoptotic pathway inpro-B cells ( Figure 7B ). These data support the hypothesis that cluding BCL-2 is a prominent target for drug development. A in the leukemic cells, but not the nonmalignant FL5.12 cells, BCL-2, is sequestering significant quantities of chronically actiprincipal mechanism whereby BCL-2 protects cells includes binding and sequestering "BH3-only" molecules, thereby prevated BH3 proteins. B: Lymphomas arising in doxycycline-treated mice usually lack human BCL-2 transgene expression. First three lanes contain lysates of leukemias from untreated triply transgenic mice. Next 7 lanes contain lysates of a lymphomas found in mice treated with doxycycline. BCL-2 immunoblot shown at top, actin immunoblot shown below. C: The leukemia is transplantable, and the leukemia is prevented by doxycycline treatment. Bone marrow cells from a leukemic mouse were injected intravenously into 13 sublethally irradiated (650 rad) recipients. WBC of untreated mice (black symbols) or mice treated with doxycycline (500 g/ml) administered in the water on the day of transplantation (red symbols) are presented. D: Transplanted mice die of leukemia, while doxycycline-treated recipients display prolonged survival. Shown is one representative cohort of three independent transplant experiments that received 2.4 ϫ 10 6 bone marrow cells from a donor with pre-B cell leukemia. Irradiated control mice that were not transplanted survived Ͼ1 year. E: Emergence of a distinct clone in a doxycycline-treated late-onset B cell lymphoma. Southern blot of immunoglobulin heavy chain gene configuration. Lane D, germline configuration of donor leukemic bone marrow. Lanes 1 and 2, bone marrows of late-onset lymphoid malignancies in doxycycline-treated transplant recipients. Lane 2 shows a new clonal rearrangement. Lanes 3 and 4, bone marrow (BM) and lymph node (LN) from untreated recipient mice that rapidly succumbed to leukemia and display the germline configuration of the donor cells.
BCL-2 would prove toxic to cancer cells. Bcl-2-null mice, while they display developmental kidney defects and loss of lymphocytes and melanocytes over time, do suggest that pharmacologic inhibition of BCL-2 may be tolerated by normal tissues for defined periods (Veis et al., 1993) . Other models conditional for the expression of transforming oncogenes including MYC (Felsher and Bishop, 1999; Pelengaris et al., 1999) , RAS (Chin et al., 1999) , BCR-ABL (Huettner et al., 2000) , and WNT (Gunther et al., 2003) have witnessed tumor regression when the oncogene expression was eliminated. The BCL-2 conditional allele examined here provides the first clear evidence that an apoptosis regulator is required for tumor maintenance.
Why is the lymphoblastic leukemia here so singularly dependent upon BCL-2? One model would hold that the initiating oncogenic event is sacrosanct, a version of a synthetic lethal mutation (Hartwell et al., 1997) . The overexpression of BCL-2, like the t(14;18) in human follicular lymphoma, occurs first. Subsequent complementary mutations would reside in other pathways and actually depend on the presence of BCL-2, making BCL-2 inviolate. A second, more broadly applicable model argues that inherent to the transformation process, all cancers violate physiological checkpoints that would normally trigger their demise, unless neutralized by an essential apoptotic defect(s) ( Figure 7C ). The latter model predicts that whether acquired early or late, aberrations in apoptosis constitute a vulnerable target for therapeutic intervention that might prove common to all cancers. For example, BAD sensitizing BH3 domain, which binds BCL-2, initiates a displacement reaction that results in the activation of BAX on the mitochondria from malignant cells, but not nonmalignant counterparts ( Figures 7A and  7B ). This provides a plausible explanation as to why the ablation defect to maintain cancer cell survival. In the case of this mouse B: Mitochondria treated as in A were examined for oligomerization of BAX, model, it is likely that MYC itself is responsible for some of the which correlates with cytochrome c release. Following peptide treatment and BMH crosslinking, an immunoblot against BAX was performed.
death signaling, either directly or indirectly inducing "BH3-only" C: Schematic representation of the requirement for BCL-2 in tumor maingenes (Iaccarino et al., 2003) . The leukemia model here provides tenance. Left, overexpressed antiapoptotic BCL-2 is required for tumor an initial proof of concept that a cancer can be killed by correctmaintenance. Right, removal (or antagonism) of BCL-2 releases BH3-only ing an apoptotic defect.
molecules resulting in the activation, oligomerization of multidomain proapoptotic BAK or BAX, the permeabilization of the mitochondrial outer membrane, cytochrome c release, and apoptotic death. Genetic aberra-
Experimental procedures
tions inherent to cancer cells violate physiological checkpoints that chronically activate BH3-only molecules, which are bound and sequestered by Production of transgenic mice BCL-2, protecting BAK, BAX from activation.
A DNA construct containing DMT targeting sequences, a minimal CMV promoter, and the tet operator sequences was electroporated into an SV129/ Jae ES cell line. The selectable marker was removed by transient expression of cre-recombinase. Correctly targeted ES cells were injected into blastoventing the activation of the lethal proapoptotic effectors BAX cysts. Chimeric progeny were bred to B6 mice and the targeted allele propagated through the germline.
and BAK (Cheng et al., 2001; Wei et al., 2001) . Accordingly, considerable efforts are underway to develop peptidomimetics
Monitoring leukemia
that mimic BH3 domains (Letai et al., 2002; Wang et al., 2000b) Leukemia was diagnosed by examination of peripheral blood smears (Dip to screen and refine small molecules that occupy the BCL-2 Quick, JorVet J-322). White blood counts (WBC) were determined by an pocket (Belli et al., 2003; Tzung et al., 2001;  automated Coulter counter or confirmed by manual counts, which gave Wang et al., 2000a) or to regulate BCL-2 by antisense apcomparable results. Manual counts were performed by examining peripheral proaches (Waters et al., 2000) . Our model provides strong supblood from a razor-nicked tail diluted in buffer (saponin 0.3%, Hoechst 33258 1 g/ml, EDTA 25 mM in phosphate-buffered saline) using a hemacytometer.
port for the heretofore untested supposition that antagonism of cals, a nonpublic company developing cell death therapeutics. Leukemic cell culture Leukemic cells from bone marrow were grown in IMDM supplemented with 10% fetal calf serum, IL-7 10 ng/ml, FLT-3 ligand 5 ng/ml, and SCF 10 ng/ml. al., 1990) . Analysis of Bax oligomers by BAX crosslinking was performed as genic mice. Nature 318, 533-538. previously described (Letai et al., 2002) . Cytochrome c was detected using Allman, D., Li, J., and Hardy, R.R. (1999) . Commitment to the B lymphoid a mouse monoclonal antibody (Pharmingen 556433). BAX was detected lineage occurs before DH-JH recombination. J. Exp. Med. 189, 735-740. using a rabbit polyclonal antibody (N-20, Santa Cruz).
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